[Federal Register: November 14, 2007 (Volume 72, Number 219)]
[Notices]
[Page 64102-64103]
[DOCID:fr14no07-89]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56759; File No. SR-NASDAQ-2007-069]

Self-Regulatory Organization; The NASDAQ Stock Market LLC; Order
Approving Proposed Rule Change and Amendment No. 1 Thereto To Amend Its
Rule Governing the Relation of a Nasdaq Market Maker's Quotations to
the Prevailing Market

November 7, 2007.
    On August 1, 2007, The NASDAQ Stock Market LLC (``Nasdaq'') filed
with the Securities and Exchange Commission (``Commission''), pursuant
to section 19(b)(1) of the Securities Exchange Act of 1934 (``Act'')
\1\ and Rule 19b-4 thereunder,\2\ a proposed rule change to eliminate a
requirement governing the relation of Nasdaq market makers' quotations
to the prevailing market. On September 19, 2007, Nasdaq filed Amendment
No. 1 to the proposed rule change. The proposed rule change, as
amended, was published for comment in the Federal Register on October
5, 2007.\3\ The Commission received no comments regarding the proposal,
and is thereby approving the proposed rule change as modified by
Amendment No. 1.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ See Securities Exchange Act Release No. 56586 (October 1,
2007), 72 FR 57085.
---------------------------------------------------------------------------

    The Commission finds that the proposed rule change is consistent
with the requirements of the Act and the rules and regulations
thereunder applicable to a national securities exchange.\4\ In
particular, the Commission finds that the proposed rule change is
consistent with section 6(b)(5) of the Act, \5\ which requires that the
rules of an exchange be designed to promote just and equitable
principles of trade, to remove impediments to and perfect the mechanism
of a free and open market and a national securities

system, and, in general, to protect investors and the public interest.
---------------------------------------------------------------------------

    \4\ In approving this proposed rule change, the Commission has
considered the proposed rule's impact on efficiency, competition,
and capital formation. See 15 U.S.C. 78c(f).
    \5\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

    Nasdaq proposes to amend Rule 4613(c) to eliminate the requirement
that a Nasdaq market maker's quotations be ``reasonably related to the
prevailing market.'' The requirement was adopted in 1987, at which time
Nasdaq was part of the National Association of Securities Dealers, Inc.
and operated an over-the-counter market with competing dealers. Nasdaq
states that the requirement is no longer meaningful, given the
regulatory changes, as well as the changes Nasdaq has made to the way
its market operates in the last 20 years. However, for each security in
which they are registered, market makers would continue to be required
to be willing to buy and sell the security for their own account on a
continuous basis and at all times maintain a two-sided, attributable
quotation that is displayed in the Nasdaq Quotation Montage. The
Commission believes that the proposal is reasonable in that it mirrors
the market maker definition set forth in section 3(a)(38) of the Act
\6\ and is consistent with market maker obligations contained in rules
of other national securities exchanges.\7\ Furthermore, the Commission
notes that Nasdaq has represented that it will carefully monitor the
performance of market makers to determine if the proposal has any
impact on the extent to which market makers quote at or near the inside
market.\8\
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78c(a)(38).
    \7\ See, e.g., NYSE Arca Rule 7.23.
    \8\ In addition, the Commission notes that this rule change does
not affect the market maker exception from the ``locate''
requirement of Regulation SHO under the Act. Rule 203(b)(2)(iii) of
Regulation SHO provides an exception from the ``locate'' requirement
for short sales executed by market makers, as defined in section
3(a)(38) of the Act, but only in connection with bona-fide market
making activities.
    To qualify for Regulation SHO's ``locate'' exception, a broker-
dealer must be both a market maker in the specific security and
engaged in bona fide market making at the time of the short sale for
which the broker-dealer is claiming the exception. Thus, a broker-
dealer's general status as a market maker or its status as a market
maker in the security being sold short does not qualify it for the
exception. Further, Regulation SHO's ``locate'' requirement applies
on a transaction-by-transaction basis and, therefore, a market maker
must determine whether it is engaged in bona fide market making for
each short sale transaction. See Securities Exchange Act Release No.
50103 (July 28, 2004), 69 FR 48008 (August 6, 2004).
---------------------------------------------------------------------------

    It is therefore ordered, pursuant to section 19(b)(2) of the
Act,\9\ that the proposed rule change (SR-NASDAQ-2007-069), as modified
by Amendment No. 1, be, and it hereby is, approved.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78s(b)(2).

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\10\
---------------------------------------------------------------------------

    \10\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
[FR Doc. E7-22164 Filed 11-13-07; 8:45 am]

BILLING CODE 8011-01-P


[Federal Register Volume 83, Number 163 (Wednesday, August 22, 2018)]
[Notices]
[Pages 42513-42514]
[FR Doc No: 2018-18072]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-2381]

The Food and Drug Administration's Comprehensive, Multi-Year
Nutrition Innovation Strategy; Extension of the Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of the comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or we) is extending the
comment period for the notice of a public meeting and request for
comments, published in the Federal Register of June 27, 2018. The
notice announced a public meeting entitled ``FDA's Comprehensive,
Multi-Year Nutrition Innovation Strategy'' and invited interested
parties to provide information on specific topics related to FDA's
Nutrition Innovation Strategy. We are extending the comment period to
give interested parties more time to comment.

DATES: FDA is extending the comment period on the notice and its
request for comment, published in the Federal Register of June 27, 2018
(83 FR 30180). Submit either electronic or written comments by October
11, 2018.

ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before October 11, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time, October 11, 2018. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are postmarked or the delivery service acceptance
receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2018-N-2381 for ``The Food and Drug Administration's Comprehensive,
Multi-Year Nutrition Innovation Strategy; Public Meeting; Request for
Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review
this copy, including the claimed confidential information, in our
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information to be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at:
https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Claudine Kavanaugh, Food and Drug
Administration, Office of Foods and Veterinary Medicine, 10903 New
Hampshire Ave., Bldg. 1, Rm. 3218, Silver Spring, MD 20993, 301-796-
4647.

SUPPLEMENTARY INFORMATION: In the Federal Register of June 27, 2018 (83
FR 30180), FDA announced that it would hold a public meeting entitled
``FDA's Comprehensive, Multi-Year Nutrition Innovation Strategy.'' The
public meeting, which we held on July 26, 2018, was intended to give
interested persons an opportunity to discuss FDA's Nutrition Innovation
Strategy and to provide input on ways to modernize FDA's approach to
better protect public health while removing barriers to industry
innovation. We stated that the topics to be addressed at the meeting
would include the following:
     Considering using a standard icon to denote the claim
``healthy'' on food labels.
     Creating a more efficient review strategy for evaluating
qualified health claims on food labels.
     Discussing new or enhanced labeling statements or claims
that could facilitate innovation to produce more healthful foods and
more healthful consumer food choices.
     Modernizing the standards of identity to provide more
flexibility for the development of healthier products, while making
sure consumers have accurate information about these food products.
     Providing opportunities to make ingredient information
more helpful to consumers.
     FDA's educational campaign for consumers about the updated
Nutrition Facts label.
    See 83 FR 30180 at 30181 to 30182.
    The notice invited interested parties to provide information on
these and other topics related to FDA's Nutrition Innovation Strategy.
We asked that comments be submitted on or before August 27, 2018.
    After the public meeting, we received several requests to extend
the comment period. The requesters asserted that the time period of 32
days was insufficient to respond fully to FDA's specific request for
comments and to ensure comprehensive public input and allow potential
respondents to thoroughly evaluate and address pertinent issues.
    We have considered the requests and are extending the comment
period for another 45 days, until October 11, 2018. We believe that a
45-day extension allows adequate time for interested persons to submit
comments while ensuring the continued forward progress of FDA's
Nutrition Innovation Strategy.

    Dated: August 16, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-18072 Filed 8-21-18; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 85, Number 54 (Thursday, March 19, 2020)]
[Notices]
[Pages 15791-15792]
[FR Doc No: 2020-05717]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-4054]

Brenda Elise Edwards: Final Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is issuing an
order under the Federal Food, Drug, and Cosmetic Act (FD&C Act)
permanently debarring Brenda Elise Edwards from providing services in
any capacity to a person that has an approved or pending drug product
application. FDA bases this order on a finding that Mrs. Edwards was
convicted of a felony under Federal law for conduct that relates to the
regulation of a drug product under the FD&C Act. Mrs. Edwards was given
notice of the proposed permanent debarment and was given an opportunity
to request a hearing to show why she should not be debarred. As of
January 2, 2020 (30 days after receipt of the notice), Mrs. Edwards had
not responded. Mrs. Edwards's failure to respond and request a hearing
constitutes a waiver of her right to a hearing concerning this action.

DATES: This order is applicable March 19, 2020.

ADDRESSES: Submit applications for special termination of debarment to
the Dockets Management Staff (HFA-305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of
Enforcement, Office of Strategic Planning and Operational Policy,
Office of Regulatory Affairs, Food and Drug Administration, 12420
Parklawn Dr., Rockville, MD 20857<EMAIL_ADDRESS>240-402-
8743.

SUPPLEMENTARY INFORMATION:

I. Background

    Section 306(a)(2)(B) of the FD&C Act (21 U.S.C. 335a(a)(2)(B))
requires debarment of an individual from providing services in any
capacity to a person that has an approved or pending

drug product application if FDA finds that the individual has been
convicted of a felony under Federal law for conduct relating to the
regulation of any drug product under the FD&C Act. On January 28, 2019,
Mrs. Edwards was convicted as defined in section 306(l)(1)(A) of the
FD&C Act when judgment was entered against her in the U.S. District
Court for the Middle District of Tennessee, Nashville Division, after
her plea of guilty, to one count of conspiracy to commit mail fraud in
violation of 18 U.S.C. 371.
    The factual basis for this conviction is as follows: As contained
in count 1 of the indictment, filed on January 17, 2013, to which Mrs.
Edwards pleaded guilty, from December 2006 through August 2009, Mrs.
Edwards, along with others, through Cumberland Distribution, Inc.
(Cumberland), a company Mrs. Edwards was an employee of, was engaged in
wholesale distribution of prescription drugs as defined by section
505(e) of the FD&C Act (21 U.S.C. 355(e)). Cumberland purchased
millions of dollars of prescription drugs from unlicensed drug
suppliers who were not authorized to distribute drugs under section 503
of the FD&C Act (21 U.S.C. 353). Mrs. Edwards knew that these
unlicensed suppliers often procured drugs from street level drug
diverters who had obtained the drugs from persons with legitimate
prescriptions. On many occasions, Mrs. Edwards, along with others, had
drugs shipped to shell companies, which Cumberland used as pass-
throughs to create the appearance that Cumberland was purchasing drugs
from licensed suppliers when in fact Cumberland was purchasing drugs
from unlicensed suppliers. Afterwards, Mrs. Edwards, along with others,
had these drugs shipped to Cumberland's Nashville warehouse where they
were re-packaged and shipped to independent pharmacies around the
country.
    Mrs. Edwards also directed Cumberland employees to take steps to
make it appear that the diverted drugs were purchased from authorized
sellers, such as by: (1) Cleaning pharmaceutical bottles to remove
evidence of glue, dirt or hair; (2) inspecting bottles for signs of
diversion, such as scratches in the label, glue residue, broken seal,
expired product, or illegible lot numbers; and (3) attaching patient
information pamphlets to bottles that did not have them. The diverted
drugs included drugs used to combat human immunodeficiency virus (HIV)/
acquired immunodeficiency syndrome (AIDS), antipsychotic medications,
anti-depressants, blood pressure medications, and diabetes medications,
among others. Through the course of this scheme, Cumberland had gross
proceeds of approximately $58,984,912. Mrs. Edwards and two others
obtained profits of approximately $14,689,782.
    As a result of this conviction, FDA sent Mrs. Edwards by certified
mail on November 18, 2019, a notice proposing to permanently debar her
from providing services in any capacity to a person that has an
approved or pending drug product application. The proposal was based on
a finding, under section 306(a)(2)(B) of the FD&C Act, that Mrs.
Edwards was convicted of a felony under Federal law for conduct
relating to the regulation of a drug product under the FD&C Act. The
proposal also offered Mrs. Edwards an opportunity to request a hearing,
providing her 30 days from the date of receipt of the letter in which
to file the request, and advised her that failure to file a timely
request for a hearing constituted an election not to use the
opportunity for a hearing and a waiver of any contentions concerning
this action. Mrs. Edwards received the proposal on December 2, 2019.
Mrs. Edwards did not request a hearing within the timeframe prescribed
by regulation and has, therefore, waived her opportunity for a hearing
and any contentions concerning her debarment (21 CFR part 12).

II. Findings and Order

    Therefore, the Assistant Commissioner, Office of Human and Animal
Food Operations, under section 306(a)(2)(B) of the FD&C Act), under
authority delegated to the Assistant Commissioner, finds that Brenda
Elise Edwards has been convicted of a felony under Federal law for
conduct otherwise relating to the regulation of a drug product under
the FD&C Act.
    As a result of the foregoing finding, Brenda Elise Edwards is
permanently debarred from providing services in any capacity to a
person with an approved or pending drug product application, applicable
(see DATES) (see section 306(a)(2)(B) and (c)(2)(A)(ii) of the FD&C
Act). Any person with an approved or pending drug product application
who knowingly employs or retains as a consultant or contractor, or
otherwise uses the services of Brenda Elise Edwards, in any capacity
during her debarment, will be subject to civil money penalties (section
307(a)(6) of the FD&C Act (21 U.S.C. 335b(a)(6))). If Mrs. Edwards
provides services in any capacity to a person with an approved or
pending drug product application during her period of debarment, she
will be subject to civil money penalties (section 307(a)(7) of the FD&C
Act). In addition, FDA will not accept or review any abbreviated new
drug applications from Mrs. Edwards during her period of debarment,
other than in connection with an audit under section 306(c)(1)(B) of
the FD&C Act. Note that, for purposes of section 306 of the FD&C Act, a
``drug product'' is defined as a drug subject to regulation under
section 505, 512, or 802 of the FD&C Act (21 U.S.C. 355, 360b, or 382)
or under section 351 of the Public Health Service Act (42 U.S.C. 262)
(see section 201(dd) of the FD&C Act (21 U.S.C. 321(dd)).
    Any application by Mrs. Edwards for special termination of
debarment under section 306(d)(4) of the FD&C Act should be identified
with Docket No. FDA-2019-N-4054 and sent to the Dockets Management
Staff (see ADDRESSES). All such submissions are to be filed in four
copies (21 CFR 10.20(a)). The public availability of information in
these submissions is governed by 21 CFR 10.20.
    Publicly available submissions may be seen in the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

    Dated: March 13, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-05717 Filed 3-18-20; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 83, Number 158 (Wednesday, August 15, 2018)]
[Notices]
[Pages 40631-40632]
[FR Doc No: 2018-17607]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2017-0060]

Qualification of Drivers; Exemption Applications; Hearing

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of final disposition.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces its decision to exempt 30 individuals from the
hearing requirement in the Federal Motor Carrier Safety Regulations
(FMCSRs) to operate a commercial motor vehicle (CMV) in interstate
commerce. The exemptions enable these hard of hearing and deaf
individuals to operate CMVs in interstate commerce.

DATES: The exemptions were applicable on June 30, 2018. The exemptions
expire on June 30, 2020.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division,<PHONE_NUMBER>, [email protected], FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
e.t., Monday through Friday, except Federal holidays. If you have
questions regarding viewing or submitting material to the docket,
contact Docket Services, telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Electronic Access

    You may see all the comments online through the Federal Document
Management System (FDMS) at: http://www.regulations.gov.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov and/or Room W12-140 on the
ground level of the West Building, 1200 New Jersey Avenue SE,
Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday,
except Federal holidays.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to http://www.regulations.gov, as described in
the system of records notice (DOT/ALL-14 FDMS), which can be reviewed
at http://www.dot.gov/privacy.

II. Background

    On May 29, 2018 FMCSA published a notice announcing receipt of
applications from 30 individuals requesting an exemption from the
hearing requirement in 49 CFR 391.41(b)(11) to operate a CMV in
interstate commerce and requested comments from the public (83 FR
24552). The public comment period ended on June 28, 2018, and one
comment was received.
    FMCSA has evaluated the eligibility of these applicants and
determined that granting exemptions to these individuals would achieve
a level of safety equivalent to or greater than the level that would be
achieved by complying with the current regulation 49 CFR 391.41(b)(11).
    The physical qualification standard for drivers regarding hearing
found in 49 CFR 391.41(b)(11) states that a person is physically
qualified to drive a CMV if that person first perceives a forced
whispered voice in the better ear at not less than 5 feet with or
without the use of a hearing aid or, if tested by use of an audiometric
device, does not have an average hearing loss in the better ear greater
than 40 decibels at 500 Hz, 1,000 Hz, and 2,000 Hz with or

without a hearing aid when the audiometric device is calibrated to
American National Standard (formerly ASA Standard) Z24.5--1951.
    49 CFR 391.41(b)(11) was adopted in 1970, with a revision in 1971
to allow drivers to be qualified under this standard while wearing a
hearing aid, 35 FR 6458, 6463 (April 22, 1970) and 36 FR 12857 (July 3,
1971).

III. Discussion of Comments

    FMCSA received one comment in this proceeding. Vicky Johnson, of
the Minnesota Department of Safety wrote that the Minnesota Department
of Safety has no objections to Gary T. Nagel obtaining a hearing
exemption.

Basis for Exemption Determination

    Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption
from the hearing standard in 49 CFR 391.41(b)(11) if the exemption is
likely to achieve an equivalent or greater level of safety than would
be achieved without the exemption. The exemption allows the applicants
to operate CMVs in interstate commerce.
    The Agency's decision regarding these exemption applications is
based on current medical information and literature, and the 2008
Evidence Report, ``Executive Summary on Hearing, Vestibular Function
and Commercial Motor Driving Safety.'' The evidence report reached two
conclusions regarding the matter of hearing loss and CMV driver safety:
(1) No studies that examined the relationship between hearing loss and
crash risk exclusively among CMV drivers were identified; and (2)
evidence from studies of the private driver's license holder population
does not support the contention that individuals with hearing
impairment are at an increased risk for a crash. In addition, the
Agency reviewed each applicant's driving record found in the Commercial
Driver's License Information System (CDLIS), for commercial driver's
license (CDL) holders, and inspections recorded in the Motor Carrier
Management Information System (MCMIS). For non-CDL holders, the Agency
reviewed the driving records from the State Driver's Licensing Agency
(SDLA). Each applicant's record demonstrated a safe driving history.
Based on an individual assessment of each applicant that focused on
whether an equal or greater level of safety is likely to be achieved by
permitting each of these drivers to drive in interstate commerce as
opposed to restricting him or her to driving in intrastate commerce,
the Agency believes the drivers granted this exemption have
demonstrated that they do not pose a risk to public safety.
    Consequently, FMCSA finds that in each case exempting these
applicants from the hearing standard in 49 CFR 391.41(b)(11) is likely
to achieve a level of safety equal to that existing without the
exemption.

IV. Conditions and Requirements

    The terms and conditions of the exemption are provided to the
applicants in the exemption document and includes the following: (1)
Each driver must report any crashes or accidents as defined in 49 CFR
390.5; (2) each driver must report all citations and convictions for
disqualifying offenses under 49 CFR part 383 and 49 CFR 391 to FMCSA;
and (3) each driver is prohibited from operating a motorcoach or bus
with passengers in interstate commerce. The driver must also have a
copy of the exemption when driving, for presentation to a duly
authorized Federal, State, or local enforcement official. In addition,
the exemption does not exempt the individual from meeting the
applicable CDL testing requirements.

V. Preemption

    During the period the exemption is in effect, no State shall
enforce any law or regulation that conflicts with this exemption with
respect to a person operating under the exemption.

VI. Conclusion

    Based upon its evaluation of the 30 exemption applications, FMCSA
exempts the following drivers from the hearing standard, 49 CFR
391.41(b)(11), subject to the requirements cited above:

Alan M. Bridgeford (NV)
Mataio Brown (MS)
Leroy Carter (OH)
Robert M. Cates (NM)
Rocky R. Chin (WA)
Ralph E. Craig (IL)
Cesar DeLeon (TX)
Brody DiPasquale (MD)
Edward J. Duhon (AL)
Lyle Eash (OH)
Richard R. Fisher (PA)
Kinberly I. Foss (CA)
Bradley Ledford (TN)
Dustin McFadden (TX)
Francisco M. Mendoza (CA)
Jack W. Mitchell (TX)
Eugene Mostepan (CA)
Steven Moorehead (OH)
Gary T. Nagel (MN)
Marcel Paul (WA)
Dexter E. Perez (WI)
Connie Ralston (GA)
Noble D. Reed (TX)
Kurt Sanders (VA)
David L. Schibilla (IL)
Pamela Singleton (TX)
Robert W. Slate (NM)
Willine D. Smith (GA)
Michael R. Tayman (ME)
Jason R. Winemiller (IL)

    In accordance with 49 U.S.C. 31315, each exemption will be valid
for two years from the effective date unless revoked earlier by FMCSA.
The exemption will be revoked if the following occurs: (1) The person
fails to comply with the terms and conditions of the exemption; (2) the
exemption has resulted in a lower level of safety than was maintained
prior to being granted; or (3) continuation of the exemption would not
be consistent with the goals and objectives of 49 U.S.C. 31136 and
31315.

    Issued on: August 9, 2018
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2018-17607 Filed 8-14-18; 8:45 am]
 BILLING CODE 4910-EX-P


[Federal Register Volume 81, Number 143 (Tuesday, July 26, 2016)]
[Rules and Regulations]
[Pages 48693-48694]
[FR Doc No: 2016-17590]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Parts 25, 121, and 129

[Docket No.: FAA-2014-0500; Amdt. Nos. 25-143, 121-375, and 129-52]
RIN 2120-AK30

Fuel Tank Vent Fire Protection; Correction

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule; correction.

-----------------------------------------------------------------------

SUMMARY: The FAA is correcting a final rule published in the Federal
Register on June 24, 2016 (81 FR 41200). In that final rule, the FAA
amended certain airworthiness regulations for transport category
airplanes to require fuel tank designs that prevent a fuel tank
explosion caused by the propagation of flames, from external fires,
through the fuel tank vents. The final rule requires a delay of two
minutes and thirty seconds between exposure of external fuel tank vents
to ignition sources and explosions caused by propagation of flames into
the fuel tank, thus increasing the time available for passenger
evacuation and emergency response. The amendments apply to applications
for new type certificates and certain applications for amended or
supplemental type certificates. The amendments also require certain
airplanes produced in the future and operated by air carriers to meet
the new standards.
    However, in that document, the amendment numbers for the final
rules were incorrect, and an airplane model number in a footnote was
incorrect. This document now posts the correct amendment numbers and
airplane model number in the footnote.

DATES: This correction is effective on July 26, 2016.

FOR FURTHER INFORMATION CONTACT: For technical questions concerning
this action, contact Mike Dostert, Propulsion and Mechanical Systems
Branch, ANM-112, Transport Airplane Directorate, Aircraft Certification
Service, Federal Aviation Administration, 1601 Lind Ave. SW., Renton,
WA 98057-3356; telephone<PHONE_NUMBER>; facsimile<PHONE_NUMBER>;
email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Background

    On June 24, 2016, the FAA published a final rule titled, ``Fuel
Tank Vent Fire Protection'' in the Federal Register (81 FR 41200).
    The intent of that rule is to prevent fuel tank explosions caused
by ignition from external ignition sources of fuel vapor either
contained in vapor spaces \1\ or exiting from vapor spaces through the
fuel tank vent outlets. Potential external ignition sources include,
but are not limited to, ground handling equipment, fuel fires that
result from refueling spills, or ground fires that follow a survivable
crash landing in which the fuel tank and the vent system remain intact.
Means to prevent or delay the propagation of flame \2\ from external
sources into the fuel tank through the fuel tank vent system \3\ would
also prevent or delay fuel tank explosions following certain accidents.
These means include flame arrestors or fuel tank inerting. This
prevention or delay would provide additional time for the safe
evacuation of passengers from the airplane and for emergency personnel
to provide assistance.
---------------------------------------------------------------------------

    \1\ A vapor space is any portion of the airplane fuel tanks and
the fuel tank vent system that, if such tanks and system held any
fuel, could contain fuel vapor.
    \2\ Flame propagation is the spread of a flame in a combustible
environment outward from the point at which the combustion started.
    \3\ A fuel tank vent system is a system that ventilates fuel
vapor from the airplane fuel tanks to the atmosphere. A fuel tank
vent system ensures that the air and fuel pressure within the fuel
tank stay within structural limits required by Sec.  25.975(a).
---------------------------------------------------------------------------

    The rule applies to applications for new type certificates and
applications for amended or supplemental type certificates on
significant product-level change projects in which title 14, Code of
Federal Regulations (14 CFR) 25.975, ``Fuel tank vents and carburetor
vapor vents,'' is applicable to a changed area. Additionally, a new
operating requirement in both 14 CFR part 121, ``Operating
Requirements: Domestic, Flag, and Supplemental Operations,'' and 14 CFR
part 129, ``Operations: Foreign Air Carriers and Foreign Operators of
U.S.-Registered Aircraft Engaged in Common Carriage,'' applies to
airplanes that are issued an original airworthiness certificate after a
specified date.
    However, the rule published with incorrect amendment numbers, ``25-
142, 21-376, and 129-53.'' Amendment number 25-142 is the same
amendment number as the rule titled ``Harmonization of Airworthiness
Standards--Fire Extinguishers and Class B and F Cargo Compartments,''
which published in the Federal Register on February 16, 2016 (81 FR
7698). Amendment numbers 21-376 and 129-53 are incorrect designations.
The correct amendment numbers for this rule are ``25-143, 121-375, and
129-52.''

    In the same publication on page 41203 in footnote number 14, the
Lockheed airplane model number referenced is ``328.'' The correct
number should be ``382.''

Correction

    In FR Doc. 2016-14454, beginning on page 41200 in the Federal
Register of June 24, 2016, make the following corrections:

Correction

    1. On page 41200, in the second column, correct the 4th header
paragraph to read as follows:
    ``[Docket No.: FAA-2014-0500; Amdt. Nos. 25-143, 121-375, and 129-
52].''
    2. On page 41203, in the second column, correct the text of
footnote number 14 to read as follows:
    ``The previously approved Lockheed 382 and Embraer flame arrestors
would not have met the 2 minute and 30 second requirement.''

    Issued under authority provided by 49 U.S.C. 106(f) and 44701(a)
in Washington, DC, on July 19, 2016.
Lirio Liu,
Director, Office of Rulemaking.
[FR Doc. 2016-17590 Filed 7-25-16; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register Volume 83, Number 113 (Tuesday, June 12, 2018)]
[Notices]
[Pages 27367-27368]
[FR Doc No: 2018-12603]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Aviation Rulemaking Advisory Committee--Transport Airplane and
Engine Subcommittee; Meeting

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a public meeting of the FAA's Aviation
Rulemaking Advisory Committee (ARAC) Transport Airplane and Engine
(TAE) Subcommittee to discuss TAE issues.

DATES: The meeting will be held on Wednesday, July 25, 2018, starting
at 1:00 p.m. Eastern Daylight Time.

ADDRESSES: This is a public teleconference.

FOR FURTHER INFORMATION CONTACT: Lakisha Pearson, Office of Rulemaking,
ARM-209, FAA, 800 Independence Avenue SW, Washington, DC 20591,
Telephone<PHONE_NUMBER>, Fax<PHONE_NUMBER>, or email at [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to Section 10(a)(2) of the Federal
Advisory Committee Act (Pub. L. 92-463; 5 U.S.C. app. III), notice is
given of an ARAC Subcommittee meeting to be held on July 25, 2018.
    The agenda for the teleconference is as follows:
     Transport Airplane Metallic and Composite Structures
workgroup final report.
     Avionics Systems Harmonization workgroup work plan.
     Flight Test Harmonization workgroup One Engine Inoperative
Controllability on Slippery Surfaces final report.
     Transport Airplane Crashworthiness and Ditching workgroup
Final Report Executive Summary.
    Participation is open to the public, but will be limited to the
availability of teleconference lines. Participation will

be by teleconference only. Please confirm your participation with the
person listed in the FOR FURTHER INFORMATION CONTACT section no later
than July 16, 2018. Please provide the following information: Full
legal name and name of your industry association, or applicable
affiliation.
    To participate, please contact the person listed in FOR FURTHER
INFORMATION CONTACT by email or phone for the teleconference call-in
number and passcode. Participants are responsible for any telephone,
data usage or other similar expenses related to this meeting.
    The public must make arrangements by July 16, 2018, to present oral
or written statements at the meeting. Written statements may be
presented to the Subcommittee by providing a copy to the person listed
in the FOR FURTHER INFORMATION CONTACT section. Copies of the documents
to be presented to the Subcommittee may be made available by contacting
the person listed in the FOR FURTHER INFORMATION CONTACT section.
    If you need assistance or require a reasonable accommodation for
the meeting or meeting documents, please contact the person listed in
the FOR FURTHER INFORMATION CONTACT section.

    Issued in Washington, DC.
Lirio Liu,
Designated Federal Officer, Aviation Rulemaking Advisory Committee.
[FR Doc. 2018-12603 Filed 6-11-18; 8:45 am]
 BILLING CODE 4910-13-P


[Federal Register Volume 85, Number 116 (Tuesday, June 16, 2020)]
[Notices]
[Pages 36399-36400]
[FR Doc No: 2020-12924]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings

    Take notice that the Commission has received the following Natural
Gas Pipeline Rate and Refund Report filings:

    Docket Numbers: RP20-911-001.
    Applicants: Rockies Express Pipeline LLC.
    Description: Tariff Amendment: REX 2020-06-03 RP20-911 Amendment to
be effective 6/1/2020.
    Filed Date: 6/3/20.
    Accession Number: 20200603-5134.
    Comments Due: 5 p.m. ET 6/15/20.

    Docket Numbers: RP20-949-000.
    Applicants: Big Sandy Pipeline, LLC.
    Description: Sec.  4(d) Rate Filing: FTS FOSA Modification--June
2020 to be effective 8/1/2020.
    Filed Date: 6/9/20.
    Accession Number: 20200609-5031.
    Comments Due: 5 p.m. ET 6/22/20.

    Docket Numbers: RP20-950-000.
    Applicants: Texas Eastern Transmission, LP.
    Description: Sec.  4(d) Rate Filing: June 2020 NRA Cleanup Filing
to be effective 7/9/2020.
    Filed Date: 6/9/20.
    Accession Number: 20200609-5066.
    Comments Due: 5 p.m. ET 6/22/20.

    Docket Numbers: RP20-951-000.
    Applicants: Texas Eastern Transmission, LP.
    Description: Sec.  4(d) Rate Filing: TETLP NRA Name Change
Cleanup--Colonial to Boston eff 7-9-20 to be effective 7/9/2020.
    Filed Date: 6/9/20.
    Accession Number: 20200609-5134.
    Comments Due: 5 p.m. ET 6/22/20.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified date(s). Protests may be considered,
but intervention is necessary to become a party to the proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: June 10, 2020.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2020-12924 Filed 6-15-20; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 78, Number 205 (Wednesday, October 23, 2013)]
[Notices]
[Page 63228]
[FR Doc No: 2013-24781]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-P-0671]

Determination That PARAFLEX (Chlorzoxazone) Tablets, 250
Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined that
PARAFLEX (Chlorzoxazone) Tablets, 250 milligrams (mg), was not
withdrawn from sale for reasons of safety or effectiveness. This
determination will allow FDA to approve abbreviated new drug
applications (ANDAs) for PARAFLEX (Chlorzoxazone) Tablets, 250 mg, if
all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Kathy Schreier, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6252, Silver Spring, MD 20993-0002, 301-
796-3432.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products under an ANDA procedure. ANDA applicants
must, with certain exceptions, show that the drug for which they are
seeking approval contains the same active ingredient in the same
strength and dosage form as the ``listed drug,'' which is a version of
the drug that was previously approved. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
    The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness (21
CFR 314.162).
    A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec.  314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
    PARAFLEX (Chlorzoxazone) Tablets, 250 mg, is the subject of NDA 11-
300, held by Ortho McNeil Pharm, and was initially approved on December
12, 1958. PARAFLEX is indicated as an adjunct to rest, physical
therapy, and other measures for the relief of discomfort associated
with acute, painful musculoskeletal conditions.
    In letters dated April 11, 1997, and April 22, 1997, a former NDA
holder, The R.W. Johnson Pharmaceutical Research Institute, notified
FDA that PARAFLEX (Chlorzoxazone) Tablets, 250 mg, had been
discontinued and requested withdrawal of NDA 11-300, and FDA moved the
drug product to the ``Discontinued Drug Product List'' section of the
Orange Book. In the Federal Register of September 25, 1997 (62 FR
50387), FDA announced that it was withdrawing approval of NDA 11-300,
effective September 25, 1997.
    Lachman Consultant Services, Inc., submitted a citizen petition
dated June 4, 2013 (Docket No. FDA-2013-P-0671), under 21 CFR 10.30,
requesting that the Agency determine whether PARAFLEX (Chlorzoxazone)
Tablets, 250 mg, was withdrawn from sale for reasons of safety or
effectiveness.
    After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec.  314.161 that PARAFLEX (Chlorzoxazone) Tablets, 250 mg, was
not withdrawn for reasons of safety or effectiveness. The petitioner
has identified no data or other information suggesting that PARAFLEX
(Chlorzoxazone) Tablets, 250 mg, was withdrawn for reasons of safety or
effectiveness. We have carefully reviewed our files for records
concerning the withdrawal of PARAFLEX (Chlorzoxazone) Tablets, 250 mg,
from sale. We have also independently evaluated relevant literature and
data for possible postmarketing adverse events. We have found no
information that would indicate that this product was withdrawn from
sale for reasons of safety or effectiveness.
    Accordingly, the Agency will continue to list PARAFLEX
(Chlorzoxazone) Tablets, 250 mg, in the ``Discontinued Drug Product
List'' section of the Orange Book. The ``Discontinued Drug Product
List'' delineates, among other items, drug products that have been
discontinued from marketing for reasons other than safety or
effectiveness. ANDAs that refer to PARAFLEX (Chlorzoxazone) Tablets,
250 mg, may be approved by the Agency as long as they meet all other
legal and regulatory requirements for the approval of ANDAs. If FDA
determines that labeling for this drug product should be revised to
meet current standards, the Agency will advise ANDA applicants to
submit such labeling.

    Dated: October 3, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-24781 Filed 10-22-13; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 78, Number 227 (Monday, November 25, 2013)]
[Proposed Rules]
[Page 70248]
[FR Doc No: 2013-28083]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Chapter I

[Docket No. FDA-2013-N-0001]

Medical Gas Regulation Review; Announcement of Public Meeting;
Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a document that
appeared in the Federal Register of November 1, 2013 (78 FR 65588). The
document announced a public meeting entitled ``Medical Gas Regulation
Review.'' The document was published with an incorrect Web site. This
document corrects that error.

DATES: Effective November 25, 2013.

FOR FURTHER INFORMATION CONTACT: Mary Gross, Office of Executive
Programs, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002,<PHONE_NUMBER>, FAX:<PHONE_NUMBER>, email:
<EMAIL_ADDRESS>or Christine Kirk, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002,<PHONE_NUMBER>, FAX:<PHONE_NUMBER>, email:
<EMAIL_ADDRESS>or Urvi Desai, Center for Veterinary
Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville,
MD 20855, email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, November
1, 2013, in FR Doc. 2013-26056, on page 65588 the following corrections
are made:
    1. In the third column, in the last sentence of the second
paragraph under Registration and Requests for Oral Presentations,
``http://www.fda.gov/Drugs/NewEvents/ucm370351.htm'' is corrected to
read ``http://www.fda.gov/Drugs/NewsEvents/ucm370351.htm''.
    2. In the third column, in the first sentence of the third
paragraph under Registration and Requests for Oral Presentations,
``http://www.fda.gov/Drugs/NewEvents/ucm370351.htm'' is corrected to
read ``http://www.fda.gov/Drugs/NewsEvents/ucm370351.htm''.

    Dated: November 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-28083 Filed 11-22-13; 8:45 am]
BILLING CODE 4160-01-P


[Federal Register Volume 82, Number 235 (Friday, December 8, 2017)]
[Notices]
[Page 57975]
[FR Doc No: 2017-26541]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[9956-82-OEI]

Cross-Media Electronic Reporting: Authorized Program Revision
Approval, State of West Virginia

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces EPA's approval of the State of West
Virginia's request to revise/modify certain of its EPA-authorized
programs to allow electronic reporting.

DATES: EPA approves the State of West Virginia's authorized program
revisions as of December 8, 2017.

FOR FURTHER INFORMATION CONTACT: Karen Seeh, U.S. Environmental
Protection Agency, Office of Environmental Information, Mail Stop
2823T, 1200 Pennsylvania Avenue NW., Washington, DC 20460, (202) 566-
1175, [email protected].

SUPPLEMENTARY INFORMATION: On October 13, 2005, the final Cross-Media
Electronic Reporting Rule (CROMERR) was published in the Federal
Register (70 FR 59848) and codified as part 3 of title 40 of the CFR.
CROMERR establishes electronic reporting as an acceptable regulatory
alternative to paper reporting and establishes requirements to assure
that electronic documents are as legally dependable as their paper
counterparts. Subpart D of CROMERR requires that state, tribal or local
government agencies that receive, or wish to begin receiving,
electronic reports under their EPA-authorized programs must apply to
EPA for a revision or modification of those programs and obtain EPA
approval. Subpart D provides standards for such approvals based on
consideration of the electronic document receiving systems that the
state, tribe, or local government will use to implement the electronic
reporting. Additionally, Sec.  3.1000(b) through (e) of 40 CFR part 3,
subpart D provides special procedures for program revisions and
modifications to allow electronic reporting, to be used at the option
of the state, tribe or local government in place of procedures
available under existing program-specific authorization regulations. An
application submitted under the subpart D procedures must show that the
state, tribe or local government has sufficient legal authority to
implement the electronic reporting components of the programs covered
by the application and will use electronic document receiving systems
that meet the applicable subpart D requirements.
    On May 9, 2016, the West Virginia Department of Environmental
Protection (WVDEP) submitted a revised application titled Environmental
Submission System (ESS) for revisions/modifications to its EPA-approved
programs under title 40 CFR to allow new electronic reporting. EPA
reviewed WVDEP's request to revise/modify its EPA-authorized programs
and, based on this review, EPA determined that the revised application
met the standards for approval of authorized program revisions/
modifications set out in 40 CFR part 3, subpart D. In accordance with
40 CFR 3.1000(d), this notice of EPA's decision to approve West
Virginia's request to revise/modify its following EPA-authorized
programs to allow electronic reporting under 40 CFR parts 50-52, 60-61,
63, 65, 122, 125, 144, 146, and 403-471 is being published in the
Federal Register:
    Part 52--Approval and Promulgation of Implementation Plans;
    Part 60--Standards of Performance for New Stationary Sources;
    Part 63--National Emission Standards for Hazardous Air Pollutants
for Source Categories;
    Part 123--EPA Administered Permit Programs: The National Pollutant
Discharge Elimination System;
    Part 145--State Underground Injection Control Programs; and
    Part 403--General Pretreatment Regulations for Existing and New
Sources of Pollution.
    WVDEP was notified of EPA's determination to approve its
application with respect to the authorized programs listed above.

Matthew Leopard,
Director, Office of Information Management.
[FR Doc. 2017-26541 Filed 12-7-17; 8:45 am]
BILLING CODE 6560-50-P